Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Present And Emerging Targeted Therapy For Metastatic Breast Cancer

V. Lorusso, Ilaria Marech, M. Giampaglia, A. Gnoni, A. Tinelli, V. Chiuri
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Breast carcinoma is a complex and heterogeneous disease and several different molecular alterations areinvolved in its pathogenesis and progression. Different growth factor receptor-driven signaling pathways sustain thegrowth and survival of breast cancer cells. Actually, three targeted agents are available for the treatment of breastcancer: trastuzumab, a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2);lapatinib, an oral available dual tyrosine-kinase inhibitor of the human epidermal growth factor receptor-1 (HER1, EGFR)and HER2; bevacizumab, a monoclonal antibody directed against the vascular endothelial growth factor (VEGF). Allthese agents demonstrated to be synergistic with chemotherapy. In addition, recently concluded clinical trials suggestthat signaling inhibitors can prevent or overcome resistance to endocrine therapy in estrogen receptor positive (ER+)breast cancer. Moreover, several other targeted drugs are under investigation in clinical trials. The aim of this review is togive a synthetic but complete picture of various targeted agents for breast cancer therapy that are under clinical trials orcurrently available in clinical practice.
This paper references
10.1200/JCO.2008.21.4437
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
K. Blackwell (2010)
10.1200/JCO.2008.26.15_SUPPL.1026
Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
K. Gelmon (2008)
Insight into ErbB signalling from the structure of the ErB2-pertuzumab complex
MC Franklin (2004)
10.1158/0008-5472.CAN-04-1168
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Edgar R. Wood (2004)
10.1158/0008-5472.SABCS11-OT3-01-17
Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.
E. Andreopoulou (2011)
10.1200/JCO.2008.21.6457
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
D. Miles (2010)
10.1056/NEJMOA064320
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
10.3816/CBC.2002.S.004
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
J. O'Shaughnessy (2002)
10.1056/NEJM200103153441101
USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER 2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER 2
Ennis (2001)
10.1007/s00280-005-0108-2
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
R. Schiff (2005)
10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
A. Buzdar (1998)
10.1200/JCO.2007.14.5482
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
J. Tabernero (2008)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1200/JCO.2007.14.0988
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
A. O'Donnell (2008)
10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6
ICI 182,780 (Faslodex™)
A. Howell (2000)
10.1016/S0959-8049(00)00239-2
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
I. Vergote (2000)
10.3816/CBC.2009.n.019
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
M. Theodoulou (2009)
10.1056/NEJMoa0900212
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
10.1200/JCO.2001.19.10.2596
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
H. Mouridsen (2001)
10.1002/ijc.21015
Herceptin‐induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down‐regulation of ErbB2
K. E. Longva (2005)
10.1200/JCO.2006.09.6826
Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
G. Schaller (2007)
10.1200/JCO.2011.29.15_SUPPL.1007
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy (2011)
10.1200/JCO.2000.18.7.1399
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
M. Kaufmann (2000)
A potent specific pure antiestrogen with clinical potential.
A. Wakeling (1991)
10.1200/jco.2009.27.15_suppl.1017
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.
C. Vogel (2009)
10.1200/JCO.2000.18.22.3758
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
J. Nabholtz (2000)
10.1200/JCO.1996.14.7.2000
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
A. Buzdar (1996)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
I Kuter (2008)
10.1200/JCO.2005.04.1764
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
N. Robert (2006)
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
F. Yakes (2002)
10.1200/JCO.2004.22.90140.515
First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group
R. Paridaens (2004)
Randomized phase II study of comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND
SL Ellard (2009)
10.1200/JCO.2009.23.3734
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
S. Johnston (2009)
10.1677/ERC.1.00992
Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
S. Johnston (2005)
10.1007/s10549-007-9885-0
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
D. Cameron (2007)
10.1016/S1359-6349(08)70543-3
NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer
C. Singer (2008)
10.1016/S0140-6736(10)60892-6
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A. Tutt (2010)
10.1056/NEJMOA072113
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
K. Miller (2007)
10.1002/BIES.20085
The PARP superfamily
J. Amé (2004)
10.1200/JCO.2007.14.1127
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.
C. Tanaka (2008)
10.1200/JCO.2002.10.057
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
A. Howell (2002)
10.1016/S1535-6108(04)00083-2
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
M. C. Franklin (2004)
10.1200/JCO.2009.27.8549
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
F. André (2010)
10.1200/JCO.2011.29.15_SUPPL.TPS116
EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.
S. Verma (2011)
10.1016/S1359-6349(09)72031-2
3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)
J. Baselga (2009)
10.1016/J.BREASTDIS.2011.03.043
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
K. Gelmon (2011)
10.1158/0008-5472.SABCS-34
PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).
I. Migliaccio (2009)
10.1200/JCO.2000.18.22.3748
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
J. Bonneterre (2000)
10.1038/416279b
Tumour biology: Herceptin acts as an anti-angiogenic cocktail
Yotaro Izumi (2002)
A study of Trastuzumab - DM 1 plus Pertuzumab versus Trastuzumab [ Herceptin ] plus a taxane in patients with metastatic breast cancer
PA Ellis
10.1158/0008-5472.SABCS-406
Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.
A. Fasolo (2009)
10.1016/J.YONC.2012.08.018
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
J. Thigpen (2012)
10.1200/JCO.2008.20.6847
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
B. Kaufman (2009)
10.1038/sj.bjc.6602930
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L. Arnould (2006)
10.1634/THEONCOLOGIST.7-5-410
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
M. Jahanzeb (2002)
10.1158/0008-5472.SABCS-09-44
A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
W. Gradishar (2009)
10.3109/08977199209023937
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.
K. Kim (1992)
10.1158/1078-0432.CCR-04-0225
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
R. Gennari (2004)
10.1002/cncr.11468
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women
J. Robertson (2003)
10.1158/0008-5472.CAN-03-3856
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
R. Nahta (2004)
10.1016/S0084-3873(11)00186-6
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
J. Thigpen (2011)
10.1038/sj.onc.1209685
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
X-F Wen (2006)
10.1200/JCO.2011.29.15_SUPPL.TPS102
MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
P. Ellis (2011)
10.1158/1078-0432.CCR-09-1764
Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance
A. Leary (2010)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1016/S0076-6879(05)07047-3
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Lila Adnane (2006)
10.1200/JCO.1998.16.2.453
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
P. Dombernowsky (1998)
10.1016/J.CANLET.2005.01.041
Herceptin: mechanisms of action and resistance.
R. Nahta (2006)
10.1200/JCO.2010.30.8213
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
M. Andersson (2011)
10.1158/1078-0432.CCR-07-4417
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Q. Chu (2008)
10.1200/JCO.2001.19.10.2722
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H. Burstein (2001)
10.1016/J.YONC.2012.08.009
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
J. Thigpen (2012)
10.1200/JCO.2011.29.15_SUPPL.TPS114
Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.
E. Andreopoulou (2011)
10.1200/JCO.2002.10.058
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
C. Osborne (2002)
10.1200/JCO.2008.21.3033
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
S. Ellard (2009)
10.1016/S0084-3873(11)00185-4
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
J. Thigpen (2011)
10.1002/cncr.11656
Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone
K. Klos (2003)
10.1038/74704
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
10.1016/S0140-6736(01)72384-7
On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases
G. Beatson (1896)



Semantic Scholar Logo Some data provided by SemanticScholar